University of Los Angeles, California (UCLA) researchers are pursuing COVID-19 via a commonly used method to treat men with prostate cancer in an effort to help drive improved clinical outcomes for individuals afflicted with SARS-CoV-2, the virus behind COVID-19. Specially, the Bruin research team teams with the U.S. VA to use a hormone suppressor in a Phase II clinical trial assessing if actually suppressing these male hormones can lessen the severity of COVID-19 as well as help the patient get better faster, reduce the total amount of hospital stay while decreasing the need for intubation all leading to improved mortality.
Males at Greater Risk
The numbers are revealing that males may be at graver risk than females in this pandemic. Hence, Matthew Rettig, MD, professor of medicine and urology at the David Geffen School of Medicine at UCLA and member of the UCLA Jonsson Comprehensive Cancer Center, commented, “it’s becoming pretty clear that men are more likely than women to die from COVID-19 and we think there is a connection between prostate cancer research and our understanding of COVID-19 research.”
In fact, as reported by UCLA’s Jonsson Comprehensive Cancer Center l...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).